Bergen, Norway, 23 April 2025 - Lifecare ASA (LIFE), a medtech company
developing next generation continuous glucose monitoring (CGM) solutions for
diabetes management, today publishes an updated company presentation
articulating the company's long-term value creation opportunity.
The presentation is attached and available at: https://lifecare.no/investor/
Key highlights from the presentation:
Diabetes is a trillion-dollar global healthcare challenge
* CGMs the fastest growing diabetes tech segment, representing a USD 30
billion market opportunity
* Within CGMs, implantable solutions represent a USD 5 billion potential
market
Strong value drivers in place 2025-2028
* Set to capitalize on "second mover" advantage, leveraging first mover
regulatory approvals in the US
* Capital efficient path to commercialization with partner-led go-to-market
strategy and minimal additional R&D
* Near-term value inflection points including veterinary market launch late
2025, CE mark in 2026, and European human market launch in 2027
Significant value creation potential
* Peak revenue potential of USD 1 billion + on realistic market assumptions
* Revenue sustainable at high levels long-term assuming conservative market
share in a growing market
* EBITDA margin of 35%+
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's main focus is to bring the
next generation of Continuous Glucose Monitoring ("CGM") systems to market.
Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42